Publication & Citation Trends
Most Cited Works
Publications
5 total
Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin PDF
Cited by 239
OpenAlex
A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor1 receptor) antagonist, in patients(pts) with advanced solid tumor(ST)
Cited by 33
Semantic Scholar
Efficacy and Safety of YM155 in Relapsed/Refractory Non-Hodgkin’s Lymphoma Patients Enrolled in a Phase I Study.
Cited by 2
OpenAlex
A phase I study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion to patients with advanced solid tumors
Cited by 21
OpenAlex
640 POSTER Phase I study of ispinesib (SB-715992), a kinesin spindle protein inhibitor, in combination with capecitabine in patients with advanced solid tumors
Cited by 10
OpenAlex
Phase I study of an anti-angiogenic agent with a novel mechanism of action E7820: Safety, pharmacokinetics (PK) and pharmacodynamic (PD) studies in patients (pts) with solid tumors.
Cited by 3
Semantic Scholar
29LB1 Late Breaking ORAL Final safety, pharmacokinetic and antitumor activity results of a phase I study of YM155, a novel survivin inhibitor, when administered by 168 hour continuous infusion
Cited by 0
Semantic Scholar
Research Topics
PARP inhibition in cancer therapy
(2)
Cancer Research and Treatments
(2)
Atrial Fibrillation Management and Outcomes
(1)
Lymphoma Diagnosis and Treatment
(1)
Cell death mechanisms and regulation
(1)
Frequent Co-Authors
Affiliations
Dartmouth–Hitchcock Medical Center
Moffitt Cancer Center
North Middlesex Hospital
Astellas Pharma (United States)